Summary
Pfizer Inc. (PFE) announced on March 17, 2017, the successful completion of a public offering of $1.065 billion aggregate principal amount of 4.20% Notes due 2047. This offering was conducted under the company's existing shelf registration statement and was managed by BNP Paribas and Deutsche Bank. The issuance of these long-term notes, maturing in 2047, provides Pfizer with additional capital. Investors should note that the terms of the notes and related agreements, including the Eighth Supplemental Indenture and a legal opinion on their validity, have been filed with the SEC as exhibits to this 8-K report. This action indicates ongoing capital management and potential funding for future operations or investments.
Key Highlights
- 1Pfizer Inc. completed a public offering of $1.065 billion in 4.20% Notes due 2047 on March 17, 2017.
- 2The offering was made pursuant to Pfizer's effective shelf registration statement filed on Form S-3.
- 3The notes were issued under an indenture dated January 30, 2001, as supplemented by an Eighth Supplemental Indenture dated March 17, 2017.
- 4Key parties involved in the offering management included BNP Paribas and Deutsche Bank AG.
- 5The filing includes Exhibit 4.2 (Eighth Supplemental Indenture) and Exhibit 5.1 (Legal Opinion on the validity of the Notes) for detailed review.
- 6This issuance represents a significant long-term debt financing activity for Pfizer.